133 related articles for article (PubMed ID: 35584718)
1. Structure-based peptide ligand design for improved epidermal growth factor receptor targeted gene delivery.
Decker S; Taschauer A; Geppl E; Pirhofer V; Schauer M; Pöschl S; Kopp F; Richter L; Ecker GF; Sami H; Ogris M
Eur J Pharm Biopharm; 2022 Jul; 176():211-221. PubMed ID: 35584718
[TBL] [Abstract][Full Text] [Related]
2. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.
Schäfer A; Pahnke A; Schaffert D; van Weerden WM; de Ridder CM; Rödl W; Vetter A; Spitzweg C; Kraaij R; Wagner E; Ogris M
Hum Gene Ther; 2011 Dec; 22(12):1463-73. PubMed ID: 21644815
[TBL] [Abstract][Full Text] [Related]
3. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.
Abourbeh G; Shir A; Mishani E; Ogris M; Rödl W; Wagner E; Levitzki A
IUBMB Life; 2012 Apr; 64(4):324-30. PubMed ID: 22362419
[TBL] [Abstract][Full Text] [Related]
4. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment.
Hailing T; Yonghong P; Yufeng Z; Haitao T
J Control Release; 2022 Sep; 349():592-605. PubMed ID: 35872181
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.
Li Z; Zhao R; Wu X; Sun Y; Yao M; Li J; Xu Y; Gu J
FASEB J; 2005 Dec; 19(14):1978-85. PubMed ID: 16319141
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.
Klutz K; Schaffert D; Willhauck MJ; Grünwald GK; Haase R; Wunderlich N; Zach C; Gildehaus FJ; Senekowitsch-Schmidtke R; Göke B; Wagner E; Ogris M; Spitzweg C
Mol Ther; 2011 Apr; 19(4):676-85. PubMed ID: 21245850
[TBL] [Abstract][Full Text] [Related]
7. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of [
Li X; Hu K; Liu W; Wei Y; Sha R; Long Y; Han Y; Sun P; Wu H; Li G; Tang G; Huang S
Nucl Med Biol; 2020; 90-91():84-92. PubMed ID: 33189948
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.
Steinborn B; Truebenbach I; Morys S; Lächelt U; Wagner E; Zhang W
J Gene Med; 2018 Jul; 20(7-8):e3041. PubMed ID: 29949222
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligands.
Lee D; Lee YM; Kim J; Lee MK; Kim WJ
Biomater Sci; 2015 Jul; 3(7):1096-104. PubMed ID: 26221943
[TBL] [Abstract][Full Text] [Related]
11. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
12. Peptide GE11-Polyethylene Glycol-Polyethylenimine for targeted gene delivery in laryngeal cancer.
Ren H; Zhou L; Liu M; Lu W; Gao C
Med Oncol; 2015 Jul; 32(7):185. PubMed ID: 26008151
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of ligand-EGFR interactions: a platform for screening targeting molecules.
Kuo WT; Lin WC; Chang KC; Huang JY; Yen KC; Young IC; Sun YJ; Lin FH
PLoS One; 2015; 10(2):e0116610. PubMed ID: 25723471
[TBL] [Abstract][Full Text] [Related]
14. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
15. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of (68)Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging.
Yu HM; Chen JH; Lin KL; Lin WJ
J Labelled Comp Radiopharm; 2015 Jun; 58(7):299-303. PubMed ID: 25997858
[TBL] [Abstract][Full Text] [Related]
17. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
[TBL] [Abstract][Full Text] [Related]
18. EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery.
Müller K; Klein PM; Heissig P; Roidl A; Wagner E
Nanotechnology; 2016 Nov; 27(46):464001. PubMed ID: 27736810
[TBL] [Abstract][Full Text] [Related]
19. Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors.
Judmann B; Braun D; Schirrmacher R; Wängler B; Fricker G; Wängler C
ACS Omega; 2022 Aug; 7(31):27690-27702. PubMed ID: 35967067
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
Go G; Park HJ; Lee JH; Yun CW; Lee SH
Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
